Details for Patent: 5,442,049
✉ Email this page to a colleague
Summary for Patent: 5,442,049
Title: | Oligonucleotides for modulating the effects of cytomegalovirus infections |
Abstract: | Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides such as ISIS 2922 are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed. |
Inventor(s): | Anderson; Kevin (Carlsbad, CA), Draper; Kenneth (Boulder, CO), Baker; Brenda (Encinitas, CA) |
Assignee: | Isis Pharmaceuticals, Inc. (Carlsbad, CA) |
Application Number: | 08/009,263 |
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 5,442,049
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,442,049
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 154947 | ⤷ Try a Trial | |||
Austria | 159025 | ⤷ Try a Trial | |||
Austria | 160353 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |